EGFR and metastatic colorectal cancer: From our analysis we conclude that as regards KRAS in metastatic colorectal cancer (mCRC) treated with an anti-EGFR antibody a neutral evolution model and not KRAS mutations provides a greater understanding of the clinical outcome.